parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	group enriched in oligodendrocytes (264 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	7 Parkinson's papers of 229	0.73
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6833

receipt 6842: GPR17 in dopamine neurons, braak

power: full sample -0.13 (p 0.603, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.08 (p 0.748, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.12 (p 0.640, n 18). could be the mix.
skeptic: leave-one-out range -0.30 to -0.04, sign flips 0; without severely affected donors -0.13 (p 0.603, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GPR17 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6841: GPR17 in oligodendrocytes, braak

power: full sample -0.10 (p 0.696, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.10 (p 0.696, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.20 (p 0.429, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to +0.03, sign flips 1; without severely affected donors -0.10 (p 0.696, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GPR17 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts